At Aristea, we are committed to bringing new medicines to patients through a focused, diligent and agile approach. Aristea is currently recruiting patients to take part in the clinical trials listed below to evaluate our lead therapeutic candidate, RIST4721.
Study RIST4721-201 is a randomized, double-blind, placebo-controlled, Phase 2a Proof of Concept (POC) study to investigate the potential for RIST4721 (300 mg once daily) to treat moderate to severe PPP. The study is currently ongoing in Canada and Germany and expected to complete in early 2020.
This trial is now enrolling. Learn more